The company expects the last relapsing-remitting multiple sclerosis patient to complete the trial by the third quarter of this year. Credit: illustrissima/Shutterstock.

Contineum Therapeutics has concluded the targeted enrolment of 168 subjects in its Phase II trial of M1 receptor antagonist PIPE-307 to treat relapsing-remitting multiple sclerosis (RRMS).

Named PIPE-307 VISTA, the randomised, double-blind, placebo-controlled, multicentre, proof-of-concept trial is evaluating the efficacy and safety of PIPE-307 in RRMS patients.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Participants will be randomised in a 1:1:1 ratio into one of three cohorts to receive two different doses of PIPE-307 or a placebo.

The study will last approximately 30 weeks and is designed to assess multiple clinical and imaging endpoints that are sensitive to changes in remyelination in RRMS patients.

The company expects the last patient to complete the trial by the third quarter of this year.

Contineum Therapeutics chief medical officer Stephen Huhn said: “We are pleased to reach this significant milestone for the PIPE-307 VISTA trial ahead of schedule.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“The trial is designed to show evidence of remyelination as a potentially first-in-class and differentiated therapy for RRMS patients. We believe that PIPE-307 could represent the next evolution in the treatment paradigm for RRMS. We are grateful for the VISTA trial investigators, patients, and their families, and we look forward to sharing topline data from this trial.”

Contineum is developing PIPE-307 under a global licence and development agreement with Janssen Pharmaceutica NV, a Johnson & Johnson company.

Apart from PIPE-307, the company is also developing a lysophosphatidic acid 1 receptor antagonist, PIPE-791, for treating idiopathic pulmonary fibrosis, progressive multiple sclerosis, and chronic pain.

In December 2024, the company dosed the first subject cohort in the Phase Ib positron emission tomography (PET) trial of brain-penetrant small molecule PIPE-791.